Cantargia AB (publ) (STO:CANTA)
2.186
+0.016 (0.74%)
Jul 3, 2026, 5:29 PM CET
Cantargia AB Revenue
Cantargia AB had revenue of 508.00K SEK in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to 317.21M. In the year 2025, Cantargia AB had annual revenue of 316.70M.
Revenue (ttm)
317.21M
Revenue Growth
n/a
P/S Ratio
1.71
Revenue / Employee
14.42M
Employees
22
Market Cap
543.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 316.70M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sprint Bioscience AB | 153.28M |
| Oncopeptides AB | 83.24M |
| Intervacc AB | 18.89M |
| Corline Biomedical AB | 10.67M |
| Medivir AB | 9.01M |
| Xspray Pharma AB | 2.47M |
| FluoGuide | 349.42K |
| Infant Bacterial Therapeutics AB | -1.00K |
Cantargia AB News
- 11 days ago - Cantargia AB Transcript: KOL event - Transcripts
- 11 days ago - Cantargia AB Press release: KOL event - Filings
- 4 weeks ago - Cantargia AB Transcript: Investor update - Transcripts
- 4 weeks ago - Cantargia AB Press release: Investor update - Filings
- 6 weeks ago - Cantargia AB Earnings Call Transcript: Q1 2026 - Transcripts
- 6 weeks ago - Cantargia AB Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Cantargia AB Slides: Q1 2026 - Filings
- 6 weeks ago - Cantargia AB Slides: Corporate presentation - Filings